[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100572210":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":22,"centralContacts":22,"locations":32,"responsibleParty":52,"collaborators":22,"id":56,"slug":22,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":22,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":22,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":35,"whyStopped":22,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Study arm","EXPERIMENTAL","Methylprednisolone combined with concurrent chemoradiotherapy",[13,14,15],"Radiation: Radiotherapy","Drug: Concurrent chemotherapy","Drug: Methylprednisolone",[17,23,28],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"RADIATION","Radiotherapy","Hypofractionated radiotherapy",[9],null,{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":22},"DRUG","Concurrent chemotherapy","weekly albumin-bound paclitaxel (50 mg\u002Fm²) and cisplatin (25 mg\u002Fm²)",[9],{"type":24,"name":29,"description":30,"armGroupLabels":31,"otherNames":22},"Methylprednisolone","Methylprednisolone 2mg\u002Fkg, qd, concurrent with radiotherapy",[9],[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Sun yat-sen University Cancer Center","RECRUITING","Guanzhou","Guangdong","510000","China",{"type":41,"coordinates":42},"Point",[43,44],113.37117,23.06828,{"lat":44,"lon":43},[47],{"name":48,"role":49,"phone":50,"phoneExt":22,"email":51},"Bo Qiu","CONTACT","862087343031","qiubo@sysucc.org.cn",{"type":53,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"PRINCIPAL_INVESTIGATOR","Hui Liu","Professor","100572210",false,"NCT06730308","Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma","A Prospective, Single-arm Phase II Study of Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma","Inclusion Criteria:\n\n* Histologically confirmed type AB or B1-3 thymoma.\n* Measurable Disease: Patients must have measurable disease as defined by RECIST (Response Evaluation Criteria in Solid Tumors).\n* Unresectable or recurrent thymoma, with the tumor confined to the chest and neck area.\n* Between the ages of 18 and 70 years, regardless of sex.\n* Eastern Cooperative Oncology Group performance status of 0 or 1.\n* No prior chest radiation.\n* Adequate organ Functions.\n* Written informed consent obtained.\n\nExclusion Criteria:\n\n* Contraindications to Methylprednisolone.\n* History of or Concurrent Malignancy.\n* Active infection, myocardial infarction within the last 6 months or symptomatic heart disease.\n* Pregnant or Lactating Women.\n* Bleeding Disorders.\n* Recent Participation in Other Clinical Trials.\n* Drug Abuse or Severe Alcoholism.\n* Uncontrolled Seizures or Mental Disorders.\n* Severe Allergies or Specific Sensitivities.","ALL","18 Years","75 Years",{"count":66,"type":67},45,"ESTIMATED","INTERVENTIONAL",[70],"PHASE2","This study aims to assess the efficacy of methylprednisolone combined with concurrent chemoradiotherapy in treating unresectable or recurrent thymoma.",[73],"Thymoma",[73,75,29],"Concurrent chemoradiotherapy","2024-12-11",{"date":78,"type":79},"2024-12-12","ACTUAL",{"date":81,"type":79},"2024-11-20",{"date":83,"type":67},"2028-11-19",{"name":5,"class":6},1]